A selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivo
Atsunori Kaneshige(University of Michigan), Shaomeng Wang(University of Michigan), Jeanne A. Stuckey(University of Michigan), Jennifer L. Meagher(University of Michigan), Wei Jiang(Zhengzhou University), Hoda Metwally(University of Michigan), Bo Wen(University of Michigan), Longchuan Bai(University of Michigan), Donna McEachern(University of Michigan), Duxin Sun(University of Michigan), Paul D. Kirchhoff(University of Michigan), Lijie Zhao(University of Michigan), Yu Wang(University of Michigan), Mi Wang(Sichuan University), Renqi Xu(University of Michigan), Hui Jiang(Army Medical University), Meilin Wang(University of Michigan)
Cited by 62
Related Papers
SAR405838: An Optimized Inhibitor of MDM2–p53 Interaction That Induces Complete and Durable Tumor Regression
|Cancer Research|2014|337
Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression
|Journal of Medicinal Chemistry|2018|261
H<sub>2</sub>O<sub>2</sub> Self‐Producing Single‐Atom Nanozyme Hydrogels as Light‐Controlled Oxidative Stress Amplifier for Enhanced Synergistic Therapy by Transforming “Cold” Tumors
|Advanced Functional Materials|2022|200
MCL-1 inhibition in cancer treatment
|OncoTargets and Therapy|2018|156